Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

BACKGROUND: Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a once-daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Taramasso, Lucia, Tatarelli, Paola, Ricci, Elena, Madeddu, Giordano, Menzaghi, Barbara, Squillace, Nicola, De Socio, Giuseppe Vittorio, Martinelli, Canio, Gulminetti, Roberto, Maggi, Paolo, Orofino, Giancarlo, Vichi, Francesca, Di Biagio, Antonio, Bonfanti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069550/
https://www.ncbi.nlm.nih.gov/pubmed/30064371
http://dx.doi.org/10.1186/s12879-018-3268-5

Ejemplares similares

Ejemplares similares